These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view]. Taguchi T Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase I inhibitors: topotecan and irenotecan. Creemers GJ; Lund B; Verweij J Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429 [No Abstract] [Full Text] [Related]
5. Topoisomerase-I inhibitors in the management of colon cancer. Willson JK Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519 [No Abstract] [Full Text] [Related]
6. FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457 [No Abstract] [Full Text] [Related]
7. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]. Lavergne O; Bigg DC Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I inhibition: a new target or new missiles? Verweij J; Schellens JH Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815 [No Abstract] [Full Text] [Related]
9. [Clinical activity spectrum of irinotecan]. Cottu PH; Extra JM; Lerebours F; Espie M; Marty M Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I inhibitors: topotecan and irinotecan. Jones SF; Burris HA Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772 [No Abstract] [Full Text] [Related]
11. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Cho LC; Choy H Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):29-39. PubMed ID: 15255165 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in topoisomerase I-targeting agents, camptothecin analogues. Kim DK; Lee N Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Burris HA; Fields SM Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144 [TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative. Mori H; Itoh N; Kondoh H; Tamaya T Eur J Cancer; 1992; 28(2-3):613. PubMed ID: 1591082 [No Abstract] [Full Text] [Related]
16. CPT-11: an original spectrum of clinical activity. Rothenberg ML Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249 [TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent efficacy of camptothecins in models of human cancer. Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512 [No Abstract] [Full Text] [Related]